Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2010, Vol. 15 ›› Issue (5): 577-583.
Previous Articles Next Articles
LU Chao1,2, WAN Jiang-bo1,2, TANG Ming-qing1,2, XIAO Wei-dong2,3, XU Rui-an1,2
Received:
2010-01-11
Revised:
2010-05-07
Online:
2010-05-26
Published:
2020-09-16
CLC Number:
LU Chao, WAN Jiang-bo, TANG Ming-qing, XIAO Wei-dong, XU Rui-an. Immunity and strategy to recombinant adeno-associated virus vector[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(5): 577-583.
[1] 许瑞安, 陈凌, 肖卫东,著. 分子基因药物学[M]. 北京: 北京大学医学出版社, 2008:2-40. [2] Kaiser J. Clinical research: Death prompts a review of gene therapy vector[J]. Science, 2007,317(5838):580. [3] Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors[J]. Gene Ther, 2008,15(11):858-863. [4] Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis[J]. N Engl J Med, 2008,358(21):2240-2248. [5] Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis[J]. N Engl J Med, 2008,358(21):2231-2239. [6] Vandenberghe LH, Wilson JM. AAV as an immunogen[J]. Curr Gene Ther, 2007,7(5):325-333. [7] Chen H, Lilley C, Yu Q, et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons[J]. Current Biol, 2006,16(5):480-485. [8] Zaiss AK, Cotter MJ, White LR, et al. Complement is an essential component of the immune response to adeno-associated virus vectors[J]. J Virol, 2008,82(6):2727-2740. [9] Huang XP, Yang YP. Innate immune recognition of viruses and viral vectors[J]. Hum Gene Ther, 2009,20(4):293-301. [10] Hensley S, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors[J]. Mole Ther, 2007,15(8):1417-1422. [11] Manno C, Glader B, Ragni M, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response[J]. Nat Med, 2006,12(3):342-347. [12] Siders WM, Shields J, Kaplan J, et al. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice[J]. Hum Gene Ther, 2009,20(1):11-20. [13] Wang LL, Figueredo J, Calcedo R, et al. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets[J]. Hum Gene Ther, 2007,18(3):185-194. [14] Xiao WD, Chirmule N, Schnell MA, et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors[J]. Mol Ther, 2000,1(4):323-329. [15] Li WS, Kong FS, Li X, et al. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye[J]. Mol Vision, 2009,15(26-29):267-275. [16] Sumner-Jones SG, Gill DR, Hyde SC. Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway[J]. J Virol, 2007,81(22):12360-12367. [17] Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adeno-associated viral vectors[J]. Gene Ther, 2009,16(1):60-69. [18] Bish LT, Morine K, Sleeper MM, et al. Adeno-associated virus (aav) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat[J]. Human Gene Ther, 2008,19(12):1359-1368. [19] Huttner N, Girod A, Perabo L, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies[J]. Gene Ther, 2003,10(26):2139-2147. [20] Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors[J]. Nat Biotechnol, 2006,24(2):198-204. [21] Mingozzi F, Maus M, Hui D, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans[J]. Nat Med, 2007,13(4):419-422. [22] Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge[J]. Gene Ther, 2008,15(11):808-816. [23] Sabatino DE, Mingozzi F, Hui DJ, et al. Identification of mouse AAV capsid-specific CD8+ T cell epitopes[J]. Mol Ther, 2005,12(6):1023-1033. [24] Halbert CL, Standaert TA, Wilson CB, et al. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure[J]. J Virol, 1998,72(12):9795-9805. [25] Wang ZJ, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression[J]. Mol Ther, 2007,15(6):1160-1166. [26] Wang QZ, Lv YH, Xu RA. Dose2response and control of adeno2 associated viral vectors based preclinical and clinical gene therapy [J]. Chin J Clin Pharmacol Ther, 2008,13(10):1182-1194. [27] Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle[J]. Mol Ther, 2009,17(1):73-80. [28] Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered[J]. PNAS, 2006,103(44):16614-16614. [29] Sumner-Jones SG, Davies LA, Varathalingam A, et al. Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways[J]. Gene Ther, 2006,13(24):1703-1713. [30] Limberis MP, Vandenberghe LH, Zhang LQ, et al. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro[J]. Mol Ther, 2009,17(2):294-301. [31] Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice[J]. J Virol, 2005,79(1):214-224. [32] Inagaki K, Piao CC, Kotchey NM, et al. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver[J]. J Virol, 2008,82(19):9513-9524. [33] Klein R, Dayton R, Tatom J, et al. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method[J]. Mol Ther, 2007,16(1):87-96. [34] Foust K D, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes[J]. Nat Biotechnol, 2009,27(1):59-65. [35] Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection[J]. Mol Ther, 2008,16(6):1073-1080. [36] Miyagi N, Rao V, Ricci D, et al. Efficient and durable gene transfer to the transplanted heart using adeno-associated virus 9 vector[J]. J Heart Lung Transplant, 2008,27(5):554-560. [37] Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine Photoreceptors[J]. J Virol, 2007,81(20):11372-11380. [38] Lotery A, Yang G, Mullins R, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina[J]. Hum Gene Ther, 2003,14(17):1663-1671. [39] Wang J H, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction[J]. PNAS, 2007,104(32):13104-13109. [40] McCarty D M. Self-complementary AAV vectors; Advances and applications[J]. Mole Ther, 2008,16(10):1648-1656. [41] Hauck B, Murphy SL, Smith PH, et al. Undetectable Transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses[J]. Mol Ther, 2009,17(1):144-152. [42] Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors[J]. Nat Protocols, 2006,1(3):1412-1428. [43] Clark KR, Liu XL, McGrath JP, et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses[J]. Hum Gene Ther, 1999,10(6):1031-1039. [44] Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography[J]. J Virol Methods, 2007,140(1-2):183-192. [45] Koerber JT, Jang JH, Yu JH, et al. Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography[J]. Hum Gene Ther, 2007,18(4):367-378. [46] Arnold GS, Sasser AK, Stachler MD, et al. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes[J]. Mol Ther, 2006,14(1):97-106. [47] Duffy A M, O'Doherty AM, O'Brien T, et al. Purification of adenovirus and adeno-associated virus: Comparison of novel membrane-based technology to conventional techniques[J]. Gene Ther, 2005,12(Suppl 1):S62-S72. [48] 许瑞安, 肖卫东, 陆辉. 一种用于基因治疗的新型细胞特异性内含microRNA结合序列的基因HAAVmir[P]. 中国, 101532024.2009-09-16. |
[1] | MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 942-948. |
[2] | WANG Lu, LI Liping, XING Xin, XU Dengqiu, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Hepatic macrophages in liver injury and repair [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1188-1195. |
[3] | RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794. |
[4] | ZHOU Li, WANG Yong, LUO Yong-wei, WANG Rong, MENG Xiang, JIA Yu-ling, LIU Xiang-yun, SUN Zu-yue. Correlation effect change of internal environmental in prostate antigen protein induced SD rat prostatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 995-1000. |
[5] | LIU Xue-ni, PEI Jin-xian, LI Xiao-liang, ZANG Guo-qing, YU Yong-sheng. Effect of blockage of Notch1 signaling on the activation of T cellular immunity in peripheral blood mononuclear cells of patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(2): 174-179. |
[6] | YAN Han, ZHOU Li, LI Dong-mei, LIU Xiang-yun, SUN Zu-yue. Study of Prostat on SD rat with nonbacterial chronic prostatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1234-1238. |
[7] | XIONG Yan-jing, DONG Qun. Immunological mechanism of allicin against Candida albicans infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 866-870. |
[8] | WANG Qiong, ZHU Xue-jun. Experimental study on astragalus polysaccharides promoting the human dendritic cells maturation in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1348-1352. |
[9] | LIU Xue-ni, PAN Qing-chun, ZANG Guo-qing, YU Yong-sheng. Structure of hepatitis B virus core protein and disablement in the hepatitis B antiviral therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1170-1173. |
[10] | DU Jun-ming, WU Ping, SUN Li-juan, LIU Jian-wen, LI Ji-yu, QUAN Zhi-wei. Nordosin enhanced inhibition of FK506 on the secretion of IL-2 by lymphocyte derived from spleen of mice in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 610-613. |
[11] | ZHANG Lian-long, DAI Min, MAO Zhao-xiang, WU Xin, ZHANG Chun-dong, ZHOU Dian-yun. Effects of ganoderma liciudm ploysaccharide seleno-κ-carageenan syrup on immune function of immunosuppression mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1381-1387. |
[12] | QIN Huai-zhou, WANG Liang, ZHAO Zhen-wei, LI Li-hong, DENG Jian-ping, QU You-zhi, SHI Hang-yu, GAO Li, GAO Guo-doug. Preliminary study on effects of mangiferin on immunologic function in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 931-934. |
[13] | WU Xin, ZHANG Chun-dong, DAI Min. Immunoloregulation effect of selenocarrageenan syrupus in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(11): 1269-1273. |
[14] | TAN Hu, QIAN Zhi-yu. Immunoloregulation effect of SK Royaljelly R-1 in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 684-686. |
[15] | JIN Yan, LIU Li, WANG Qing-wei, WANG Zhi-peng, LI Yu-hua, FENG Juan, MEI Qing-bing. Effect of diethylstilbestrol on TNBS-induced colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(2): 168-172. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||